Persistent severe visual and electroretinographic abnormalities after intravenous cisplatin therapy

Journal of Neuro-Ophthalmology

Volumn 23, Issue 2, 2003, Pages 132-135

  Katz, Bradley J ^a,b   Ward, John H ^b   Digre, Kathleen B ^a,b   Creel, Donnell J ^a   Mamalis, Nick ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADULT; ARTICLE; AUTOPSY; CASE REPORT; ELECTRORETINOGRAPHY; HUMAN; MALE; NONHODGKIN LYMPHOMA; PHOTORECEPTOR; PRIORITY JOURNAL; SALVAGE THERAPY; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CISPLATIN; ELECTRORETINOGRAPHY; FATAL OUTCOME; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; OVERDOSE; RETINA; SALVAGE THERAPY; SCOTOMA; VISION DISORDERS; VISUAL ACUITY;

EID: 0037642320     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200306000-00005     Document Type: Article

References (17)

1. Richards SC, Creel DJ. Pattern dystrophy and retinitis pigmentosa caused by a peripherin/RDS mutation. Retina 1995;15:68-72.
2. Fraunfelder FT, Fraunfelder FW. Drug-Induced Ocular Side Effects, edn 5. Boston: Butterworth Heinemann, 2001:446-450.
3. Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985;3:1683-9.
4. Stewart DJ, Wallace S, Feun L, et al. A phase I study of intracarotid artery infusion of cis- diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors. Cancer Res 1982;42: 2059-62.
5. Feun LG, Wallace S, Stewart DJ, et al. Intracarotid infusion of cisdiamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 1984;54:794-9.
6. Tang R, Marroquin G, Feun LG. Ocular toxicity and intracarotid infusion of cisplatin. Cancer Bull 1985;37:35-37.
7. Kupersmith MJ, Frohman LP, Choi IS, et al. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988;38:284-9.
8. Maiese K, Walker RW, Gargan R, et al. Intra-arterial cisplatin-associated optic and otic toxicity. Arch Neurol 1992;49:83-6.
9. Miller DF, Bay JW, Lederman RJ, et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985;92:402-6.
10. Kupersmith MJ, Seiple WH, Holopigian K, et al. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 1992;113:435-8.
11. Marmor MF. Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol 1993;84:237-46.
12. Walsh TJ, Clark AW, Parhad IM, et al. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982;39:719-20.
13. Fishman GA, Birch DG, Holder GE, et al. Electrophysiologic Testing in Disorders of the Retina, Optic Nerve, and Visual Pathway, edn 2. San Francisco: Foundation of the American Academy of Ophthalmology, 2001:88-99.
14. Bernstein PS, Digre KB, Creel DJ. Retinal toxicity associated with occupational exposure to the fish anesthetic MS-222. Am J Ophthalmol 1997;124:843-4.
15. Thirkill CE, Roth AM, Keltner JL. Paraneoplastic retinopathy syndrome. Ophthalmology 1993;100:147.
16. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001;21:173-87.
17. To KW, Thirkill CE, Jakobeic FA, et al. Lymphoma-associated retinopathy. Ophthalmology 2002;109:2149-53.